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Abstract 
The reduced diameter of skeletal myofibres is a hallmark of several congenital myopathies, yet the 
underlying cellular and molecular mechanisms remain elusive. In this study we investigated the role 
of HACD1/PTPLA, involved in the elongation of the very long chain fatty acids, in muscle fibre 
formation. In humans and dogs, HACD1 deficiency leads to a congenital myopathy with fibre size 
disproportion associated with a generalized muscle weakness. Through analysis of 
HACD1-deficient Labradors, Hacd1-knockout mice and Hacd1-deficient myoblasts, we provide 
here evidence that HACD1 promotes myoblast fusion during muscle development and regeneration. 
We further demonstrated that in normal differentiating myoblasts, expression of the catalytically 
active HACD1 isoform, encoded by a muscle-enriched splice variant, yields a decrease in 
lysophosphatidylcholine content, a potent inhibitor of myoblast fusion, and an increase in 
concentrations of ≥C18 and monounsaturated fatty acids of phospholipids. These lipid 
modifications correlated with a reduction in plasma membrane rigidity. In conclusion, we propose 
that fusion impairement constitutes a novel, non-exclusive pathological mechanism operating in 
congenital myopathies and reveal that HACD1 is a key regulator of a lipid-dependent muscle fibre 
growth mechanism. 
Keywords:  
Centronuclear myopathy; LPC; MUFA; Protein Tyrosine Phosphatase-like, member A; VLCFA 
Abbreviations:  
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Main Text 
Introduction 
Congenital myopathies are rare hereditary diseases often characterized by muscle weakness 
leading to physical motor impairment that ranges from mild to life-threatening disabilities 
(North, 2008). Several of these myopathies, including myotubular/centronuclear myopathies 
(CNM) and other myopathies with congenital fibre size disproportion, demonstrate early 
myofibre hypotrophy (Jungbluth et al., 2008; North, 2008; Romero, 2010). However, the 
underlying pathogenic mechanisms remain largely unknown. 
In dogs and humans, HACD1 (3-hydroxyacyl-CoA dehydratase 1) deficiency has been 
associated with recessive congenital myopathies characterized by early-onset muscle 
weakness (Muhammad et al., 2013; Pelé et al., 2005). Early postnatal heterogeneity in 
myofibre size has been reported in both species, whereas progressive nuclear centralization 
has been observed in diseased dogs, a hallmark of CNM (Tiret et al., 2003). HACD1 encodes 
an endoplasmic reticulum (ER)-resident enzyme that interacts with ELOVL1-7, KAR and 
TER proteins to form a complex involved in the synthesis of very long chain fatty acids 
(VLCFAs) (Ikeda et al., 2008; Ohno et al., 2010). As opposed to fatty acids up to C16, 
synthesized by a cytosolic fatty acid synthase, the longer VLCFAs are elongated within the 
ER in a four-step cycle (Kihara, 2012). In mammals, four paralogous genes encoding 
HACD1-4 catalyze the third step of this elongation cycle (Ikeda et al., 2008). 
Following their incorporation into membrane lipids (such as phospholipids and 
sphingolipids), VLCFAs elicit specific functions based on their chain length and degree of 
unsaturation (Guillou et al., 2010; Kihara, 2012). In particular, they promote strong 
membrane curvature and vesicle fusion (Molino et al., 2014; Schneiter et al., 2004). In yeast, 
VLCFA elongation complex displays physical interactions with the desaturase enzyme that 
catalyzes the unsaturation of fatty acids (Miller et al., 2005), indicating interconnections 
between pathways involved in lipid balance. Although Hacd1 deficiency was reported to 
impair myoblast growth and differentiation in vitro (Lin et al., 2012), no molecular role for 
HACD1 has yet been reported in muscle cells. 
We hypothesized that heterogeneity of muscle fibre size in HACD1-related myopathies 
reflects a defect in muscle fibre development, due to altered lipid balance. Muscle fibre 
development occurs from embryogenesis through the early postnatal development and can be 
recapitulated in adults following muscle injury. During myofibre development, 
mononucleated precursor cells, called myoblasts, differentiate through a well-defined process 
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(Buckingham, 2001; Bentzinger et al., 2012). Myoblasts are derived from embryonic 
precursors or adult muscle satellite stem cells and once activated, are committed to a 
myogenic program via a cascade of transcription factor activation that triggers myoblast 
fusion, leading to the formation of large, multinucleated myofibres able to generate contractile 
force. A wealth of accumulated in vivo data strongly suggests that myoblast fusion is a 
limiting step for optimal myofibre growth, muscle mass and regenerative capacity (Horsley et 
al., 2001; Doherty et al., 2005; Georgiadis et al., 2007; Laurin et al., 2008; Hochreiter-
Hufford et al., 2013; Millay et al., 2013; Lenhart et al., 2014; Millay et al., 2014). Similar to 
other processes involving membrane fusion (Chernomordik and Kozlov, 2005), myoblast 
fusion is the result of a complex interplay between lipids and proteins, which specific roles 
are just now being unraveled (Abmayr and Pavlath, 2012; Aguilar et al., 2013). A drop in 
membrane rigidity, known to promote membrane fusion in other cellular contexts (Maxfield 
and Tabas, 2005), is observed just before myoblast fusion (Prives and Shinitzky, 1977), and 
modifications in membrane lipid composition, putatively yielding a raise in membrane 
fluidity, have been reported during myoblast differentiation (Nakanishi et al., 2001; Briolay et 
al., 2013). Giving further support that lipids have an important role in regulating membrane 
fusion, adding unsaturated fatty acids to the culture media that purportedly increase 
membrane fluidity increases the capacity of myoblasts to fuse (Prives and Shinitzky, 1977; 
Nakanishi et al., 2001; Lee et al., 2009; Briolay et al., 2013). In contrast, 
lysophosphatidylcholine, which inhibits lipid bilayer fusion due to its inverted cone shape 
(Chernomordik and Kozlov, 2005), prevents myoblast fusion when added to culture media 
(Leikina et al., 2013). Altogether, these data suggest a model where naturally occurring 
modifications of the lipid membrane composition and concomitant alterations in fluidity 
would play key role in myoblast fusion. However, little is known regarding the genetic 
control of these modifications; in addition, the physiological and clinical relevance of 
modifications in composition and fluidity of myoblast membrane has yet to be investigated. 
Given the enzymatic function of HACD1 and its implication in muscle homeostasis, we 
decided to address its precise role in muscle fibre development in the light of its molecular 
properties. We investigated this role by using combined in vitro and in vivo experiments in 
mice and dogs. 
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Results 
HACD1 is required for muscle fibre growth 
HACD1 loss-of-function mutations have been associated with congenital myopathies in 
humans and dogs (Pelé et al., 2005; Muhammad et al., 2013). To confirm the causative role of 
HACD1 deficiency in skeletal muscle impairment, we generated Hacd1-knockout mice using 
a recombinant null allele inserting the LacZ reporter gene (Supplementary Figure 1A-C). 
Heterozygous mice for the knockout allele were morphologically and histologically 
indistinguishable from their wild type littermates, in accordance with the recessive inheritance 
pattern of HACD1 mutation in human and dog (Pelé et al., 2005; Muhammad et al., 2013); 
they were used alongside wild type mice as controls. In contrast, homozygous mice for the 
knockout allele (hereafter Hacd1-/- mice), although viable and fertile, presented a reduced 
body weight gain after birth (Figure 1A). At one week of age, body weight of Hacd1-/- mice 
was reduced by 14.6% compared to control mice (P < 0.01). The reduced weight gain was 
never compensated in adulthood despite a normal body size (Supplementary Figure 1D), with 
a 15.2% and a 16.4% reduction in body weight at 12 wk and 6 mo of age compared to control 
mice, respectively (P < 0.05 and 0.01, respectively). This reduction in body weight could be 
more specifically attributed to a 29% reduction in muscle weight (Figure 1B and C) and 
correlated with a 27.5% reduction in the muscle absolute maximal force compared to controls 
(Figure 1D), however leaving specific maximal force unchanged (Supplementary Figure 1E). 
In accordance with a deleterious muscle weakness, Hacd1-/- mice often displayed kyphosis 
(Supplementary Figure 1F). 
This phenotype was reminiscent of that of HACD1-deficient Labrador retrievers (hereafter 
HACD1cnm/cnm or CNM dogs; (Tiret et al., 2003; Maurer et al., 2012)). As for Hacd1-/- mice, 
CNM dogs had reduced weight gain in the first weeks of life compared with controls 
(Supplementary Figure 2A). Postural and locomotor weakness was obvious between 2 and 6 
mo of age and histological analyses of skeletal muscles from 5-mo-old CNM-affected pups 
revealed that amyotrophy was accompanied by heterogeneity in muscle fibre diameter (Figure 
2A and B). Comparative studies between CNM dogs and Hacd1-/- mice (Figure 2A,B and 
E,F) revealed that in both cases, the mean myofibre diameter was reduced by 29.7 and 22.3% 
respectively (Figure 2C and 2G) and the distribution of fibre diameters was shifted towards 
smaller diameters in comparison with controls (Figure 2D and 2H); in Hacd1-/- mice, the 
number of myofibres per muscle was unchanged (Figure 2I), indicating that fibre hypotrophy 
per se yielded the reduced muscle mass.  
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These data suggested an early requirement of HACD1 during muscle development and an 
important role for muscle fibre growth. 
Hacd1 is required for optimal myoblast fusion  
In order to characterize the cause of the reduced muscle mass and further discriminate 
between muscle atrophy and hypotrophy, we recapitulated myofibre development during 
muscle regeneration in both dogs and mice. The course of regeneration was similar in 
controls, CNM dogs and Hacd1-/- mice. Four to 6 days after notexin-induced injury, massive 
muscle necrosis and cellular infiltration were observed (Supplementary Figure 1G and 2C), 
replaced at Day 15 by regenerating myofibres (Figure 3A, B, D, E, G, H and Supplementary 
Figure 2C). However, newly formed myofibres were already significantly hypotrophic and 
the largest myofibres were almost completely absent in CNM dogs and Hacd1-/- mice (Figure 
3C, F, I and J), identifying myofibre hypotrophy as a pathogenic mechanism. This reduced 
diameter of fibres was still present at Days 30 and 90 of regeneration in CNM dogs 
(Supplementary Figure 2C), indicating that no compensatory growth overcame this 
developmental defect. It is well-accepted that a deficit in muscle fibre growth observed at this 
stage of regeneration results from a defect in myoblast fusion (Horsley et al., 2001; Doherty et 
al., 2005; Georgiadis et al., 2007; Hochreiter-Hufford et al., 2013; Lenhart et al., 2014; Millay 
et al., 2014). Accordingly, nuclear counts at Day 15 confirmed that myofibres containing two 
nuclei were over-represented in Hacd1-/- mice compared to controls, whereas myofibres with 
7 nuclei (the highest number counted at this stage) were depleted (Figure 3K). 
To further confirm the impairment of myoblast fusion and determine if this defect was 
combined with a depletion in satellite cells, we first assessed in mice muscles the number of 
Pax7-positive satellite cells from which myoblasts differentiate to form new myofibres. Both 
immunofluorescence and RT-qPCR experiments indicated a similar expression of Pax7 in 
Hacd1-/- mice compared to controls (Supplementary Figure 3A-D), excluding reduced 
numbers of satellite cells as causative of hypotrophy. We then used the capacity of primary 
myoblasts isolated from young pups to differentiate in vitro to characterize the contribution of 
Hacd1 in fusion. After 2 days of differentiation, cells isolated from control and Hacd1-/- pups 
similarly formed myotubes and the number of nuclei within Myosin Heavy Chain-positive 
cells was similar, indicating normal myoblast commitment into the differentiation process 
(Figure 4A-C). In contrast, myotubes were globally smaller in cultures from Hacd1-/- pups 
and presented a reduced fusion index assessed by the average number of nuclei per myotube 
(Figure 4A, B and D). Accordingly, distribution of myotubes with respect to their number of 
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nuclei revealed fewer myotubes with ≥ 6 nuclei, and greater numbers of small myotubes with 
only 2 nuclei compared with controls (Figure 4E). 
Together, these results demonstrate that both in dogs and mice, Hacd1 function triggers the 
optimal fusion of myoblasts during their differentiation, sustaining the normal growth of 
muscle fibres within muscles. 
The muscle-enriched Hacd1-fl isoform is upregulated during muscle development 
and regeneration 
During embryogenesis of Hacd1+/- mice, strong expression of the LacZ reporter gene was 
observed in heart and skeletal muscle precursors (Figure 5A). LacZ expression was also 
highly induced in adult skeletal muscles during injury-induced regeneration (Figure 5B) and, 
more precisely, in regenerating myofibres recognizable by the alignment of central nuclei 
(Figure 5C). 
In wild type dogs, two HACD1 splice variants are expressed in normal skeletal muscles: the 
HACD1-fl full-length isoform retains the seven exons of the gene whilst the HACD1-d5 
isoform lacking exon 5 encodes a truncated protein (Pelé et al., 2005). RT-PCR conditions 
designed to amplify both variants revealed a broad expression of the Hacd1-d5 isoform in 
mouse tissues (Figure 5D). In contrast, Hacd1-fl expression was nearly restricted to the heart 
and skeletal muscles, and in these tissues it was the predominant, highly-expressed isoform. 
During mouse embryonic development, a shift in Hacd1 splicing occurred between day 7 and 
17, with a marked increase in Hacd1-fl expression at the expense of Hacd1-d5 (Figure 5D). 
This embryonic period spans muscle fibre maturation (Buckingham, 2001). To evaluate 
whether these two variants would play specific dynamic roles during muscle growth, we 
investigated by RT-(q)PCR their temporal expression during in vitro differentiation of wild 
type mouse primary or normal C2C12 myoblasts. We observed that formation of myotubes 
followed a marked upregulation of Hacd1-fl expression whereas Hacd1-d5 expression was 
only mildly increased or did not change in both primary myoblasts (Figure 5E,F) and C2C12 
(Figure 5G,H). In vivo, Hacd1 was also markedly induced during muscle regeneration, 
strengthening Hacd1-fl predominance over Hacd1-d5 in muscles (Figure 5I). Expression of 
Hacd2 and Hacd3 did not change during differentiation (Supplementary Figure 3E). 
HACD1-FL is necessary for myoblast fusion  
HACD1-FL protein is a vertebrate ortholog of the yeast enzyme Phs1 and displays HACD 
activity (Ikeda et al., 2008). In addition, we reported above a broad expression of Hacd1-d5 in 
mouse tissues; besides, HACD1-167, an aberrant splice variant retaining exons 1, 6 and 7, 
specifically accumulated in muscles from CNM dogs (Pelé et al., 2005). We thus investigated 
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whether the two HACD1-D5 and HACD1-167 proteins encoded by these isoforms, predicted 
respectively to exhibit two or three transmembrane domains instead of the six identified in 
HACD1-FL (Supplementary Figure 4A), shared cellular and molecular features with 
HACD1-FL. In myogenic cells, all three isoforms correctly localized to the ER. In addition, 
HACD1-FL, HACD1-D5, HACD1-167, as well as HACD2, HACD3 and HACD4 physically 
interacted with all other proteins of the elongation complex, with the exception of HACD1-
D5 that did not interact with TER (Supplementary Figure 4B-D). In vitro, enzymatic assays 
revealed that HACD1-FL, but neither HACD1-D5 nor HACD1-167, catalyzed the 
dehydration of 3-hydroxypalmitoyl-CoA into 2,3-trans-hexadecenoyl-CoA, in a dose-
dependent manner (Figure 6A and Supplementary Figure 4E). Accordingly, in vivo 
expression of HACD1-FL, but not HACD1-D5, HACD1-167 or HACD1-FL-Y171A in which 
the Y171 essential residue (Kihara et al., 2008) had been mutated, rescued cell growth arrest 
of PHS1-shutdown yeasts (Figure 6B and Supplementary Figure 4F).  
To decipher the relative functional importance of HACD1 isoforms during muscle cell 
differentiation, we stably knocked down Hacd1 expression in C2C12 cells using a small 
hairpin interfering RNA targeting the wild type Hacd1-fl and Hacd1-d5 isoforms 
(Supplementary Figure 5A). Myotube formation was severely impaired in Hacd1-knocked 
down (sh-Hacd1) cells (Figure 6C), confirming previous data (Lin et al., 2012). Defective 
fusion events were highlighted by a severe reduction in the number of nuclei per sh-Hacd1 
myotube, compared to controls (Figure 6C and D), although commitment of sh-Hacd1 cells 
into the differentiation process was confirmed by increased expression of the Myogenin and 
Myosin, heavy polypeptide 2, skeletal muscle, adult (Myh2) myogenic markers 
(Supplementary Figure 5B-D) in line with the phenotype of the Hacd1-/- myoblasts (Figure 
4A and B). This phenotype was thus consistent with our in vivo experiments that revealed an 
impairment in myoblast fusion upon HACD1 deficiency.  
To evaluate the function of each isoform, we transduced sh-Hacd1 cells with retroviral 
vectors driving the expression of shRNA-insensitive sequences encoding each of them 
(sh-Hacd1+isoform cells) (Supplementary Figure 5E and F). Importantly, rescue of the fusion 
impairment could be elicited only when the catalytically active HACD1-FL isoform was 
expressed, demonstrating the essential role of its specific activity in myoblast fusion (Figure 
6C and D). 
In parallel, sh-Hacd1 cells exhibited a reduced proliferation rate (data not shown), as 
previously reported with the same interfering sequence (Lin et al., 2012). However, in our 
hand, this phenotype was neither rescued by HACD1-FL nor by HACD1-D5 and hence likely 
resulted from an off-target effect of the RNA interference. The fact that HACD1-FL could 
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rescue the fusion defect without rescuing the proliferation defect further indicates that the 
proliferation rate did not interfere with the fusion capacity of sh-Hacd1 cells. 
HACD1-FL regulates lipid balance and membrane fluidity 
To identify the putative HACD-dependent changes in lipid content during myoblast 
differentiation, we compared phospholipid fatty acid contents in proliferative C2C12 
myoblasts, when the Hacd1-fl to Hacd1-d5 ratio was the lowest, with those at Day 3 of 
differentiation, corresponding to one day after the peak of Hacd1-fl expression (Figure 5G,H 
and Supplementary Figure 3E).  
As lysophosphatidylcholine (LPC) acts as a potent inhibitor of myoblast fusion when added to 
the differentiation medium (Leikina et al., 2013), we first evaluated whether the relative 
content of phospholipid species would be modified upon Hacd1 modulation (Supplementary 
Table 2). In control myoblasts, differentiation was accompanied by a nearly two-fold drop in 
LPC that was abolished in sh-Hacd1 myoblasts and fully restored in sh-Hacd1+FL cells 
(Figure 7A and Supplementary Table 2A). This global dynamic profile was underlain by the 
individual profile of most LPCs (Supplementary Table 2B). This result demonstrated that 
HACD1-FL activity is responsible for the drop in LPC content preceding fusion. Myoblast 
differentiation was also accompanied by an increase in the level of phosphatidylinositols and 
a decrease in lysophosphatidylethanolamines that were independent of Hacd1 expression 
(Supplementary Table 2A). 
In parallel, we evaluated fatty acid content in the whole phospholipid pool (Supplementary 
Table 3). As C18 species are the smallest fatty acids produced by the VLCFA elongation 
complex (Ohno et al., 2010), the ratio of C18-C26/C10-C16 fatty acids reflected the 
elongation efficiency. Compared to controls, the ratio was decreased in sh-Hacd1 cells both in 
proliferation and in differentiation, and this elongation defect was alleviated by HACD1-FL 
re-expression whereas it was amplified following HACD1-D5 expression (Figure 7B and 
Supplementary Table 3A and B). These results confirmed a positive role of HACD1-FL in the 
elongation of ≥C18 fatty acids and revealed an antagonistic role for HACD1-D5. 
Accordingly, the increase in the Hacd1-fl to Hacd1-d5 ratio reported above in differentiating 
control myoblasts was accompanied by an increase in the C18-C26/C10-C16 ratio (Figure 7B 
and Supplementary Table 3B). 
Interactions between the yeast desaturase Ole1 and the VLCFA elongation complex have 
been described (Miller et al., 2005). To evaluate whether such an interaction could be 
conserved and functional in mammals, we investigated the saturation status of phospholipid 
fatty acids in myoblasts. Indeed differentiating sh-Hacd1 myoblasts had an increased 
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saturated fatty acid (SFA) content, at the expense of monounsaturated fatty acids (MUFA) 
(Figure 7C and Supplementary Table 3C). Re-expression of HACD1-FL fully restored normal 
SFA and MUFA contents and slightly increased the polyunsaturated fatty acid (PUFA) 
content. During proliferation too, HACD1-FL promoted MUFA accumulation at the expense 
of SFA and HACD1-D5 isoform exhibited an antagonist role (Supplementary Figure 6A and 
Supplementary Table 3C).  
Unsaturation of fatty acids contained in phospholipids is known to increase fluidity of lipid 
bilayers (Maxfield and Tabas, 2005). To check whether the altered contents of SFA, MUFA 
and PUFA could have a functional impact on myoblasts, we analyzed their plasma membrane 
fluidity at Day 3 of differentiation and found that it was reduced by 9% in sh-Hacd1 cells at 
37°C (P = 5.10-5). Fluidity was fully restored by HACD1-FL re-expression (Figure 7D and 
Supplementary Figure 6B). 
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Discussion 
We showed that HACD1-deficient mice and dogs exhibit an early-onset hypotrophy of 
myofibres that could be recapitulated during muscle regeneration after injury, two 
characteristics of myoblast fusion impairment (Horsley et al., 2001; Doherty et al., 2005; 
Georgiadis et al., 2007; Laurin et al., 2008; Hochreiter-Hufford et al., 2013; Millay et al., 
2013; Lenhart et al., 2014; Millay et al., 2014). Defective myoblast fusion upon HACD1 
deficiency was confirmed both in vivo and in vitro, as indicated by smaller myofibres 
containing fewer nuclei. Such an early phenotype could be the result of a defect either in 
myoblast differentiation or in myoblast fusion per se. On the contrary to previously published 
data (Lin et al., 2012), we observed a normal commitment of both primary myoblasts and 
C2C12 cells into the differentiation upon Hacd1 deficiency; in both cases, we reproducibly 
showed at the RNA and protein levels that Hacd1 deficiency neither impaired Myogenin and 
Myh2 expression nor reduced the proportion of cells positive for MHC, a marker of terminal 
differentiation. This demonstrates that myoblast fusion step was more specifically affected by 
Hacd1 deficiency. 
On the molecular level, we showed that during myoblast differentiation, HACD1-FL activity 
prompts a drop in the content of LPC, an inhibitor of myoblast fusion (Leikina et al., 2013). 
In parallel, it promoted a slight increase in ≥C18 fatty acids, a rise in MUFA content and a 
drop in plasma membrane rigidity. We propose a model in which HACD1-FL upregulation 
during myoblast differentiation modifies membrane lipid balance and its physical properties 
to promote efficient fusion, eventually leading to optimal muscle mass and force (Figure 7E). 
In CNM dogs (Pelé et al., 2005), exchange of wild type HACD1 transcripts by those of the 
HACD1-167 isoform (which encodes an inactive protein), mimics the human condition in 
which a non-sense mutation abrogates the HACD activity of the encoded protein (Muhammad 
et al., 2013). As the presence of small myofibres is also observed in HACD1-deficient 
humans, we suggest that defective myoblast fusion constitutes a novel, non-exclusive 
pathological mechanism that participates to the reduction in muscle mass and strength 
observed upon HACD1 deficiency. More generally, myofibre heterogeneity with hypotrophic 
fibres is an early feature of other myopathies with congenital fibre size disproportion and 
CNM/MTM myopathies (Jungbluth et al., 2008; North, 2008; Nance et al., 2012). 
Importantly, small fibre diameter, but not the proportion of central nuclei, is associated with 
the most severe MTM1 mutations and constitutes the worst outcome in myotubular patients 
(Pierson et al., 2007). Hence we propose that defective myoblast fusion might constitute a 
synergistic pathogenic mechanism operating in these congenital myopathies (Ravenscroft et 
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al., 2014). If confirmed, a fusion defect would have direct medical consequences, as it will be 
mandatory to envisage its early correction within the very first period of postnatal life. 
Additional mechanisms underlying the accompanying concomitant development of 
hypertrophic fibres in some cases of myopathies with congenital fibre size disproportion 
(Jungbluth et al., 2008; Muhammad et al., 2013), would also need to be assessed. Importantly, 
no major cardiovascular phenotype could be observed in HACD1-deficient young adult dogs 
and mice, which heart and cardiovascular parameters were thoroughly evaluated using 
electrocardiography, arterial blood pressure measurement, echocardiography and 
tissue-doppler imaging (data not shown). Of note, in contrast to skeletal muscles, heart 
development does not rely on cell fusion events. This developmental difference may 
contribute to protecting the heart from morbid consequences of HACD1-deficiency; it also 
highlights the pathogenic role of fusion impairment in skeletal muscles. 
Changes in membrane fluidity and the degree of saturation of membrane fatty acids each 
influence myoblast fusion (Prives and Shinitzky, 1977; Nakanishi et al., 2001; Briolay et al., 
2013). Our results emphasize that Hacd1 may play a pivotal role in the integrated genetic 
control of these previously reported changes, as well as in the newly identified drop in LPC 
level. During myofiber development, Hacd1-fl is upregulated and counteracts the Hacd1-d5 
ubiquitous isoform that exerts an antagonistic role through a still unknown mechanism. As a 
direct consequence of its 3-hydroxyacyl-CoA dehydratase activity in the VLCFA elongation 
complex (Ikeda et al., 2008), HACD1-FL promoted an increase in the C18-C26 to C10-C16 
ratio during myoblast differentiation. Our data also revealed indirect key functions of Hacd1 
that were not predicted by its HACD activity, which consist in an increased MUFA content at 
the expense of SFA content and in a drop in both membrane rigidity and LPC content. While 
there are growing evidences of structural and functional interactions between enzymes of 
different lipid pathways that we did not investigate in this study, our results suggest a 
significant interplay of these pathways during myoblast fusion and indicate that Hacd1 plays 
a key role in their integrated regulation. These results also open novel medical avenues, as 
manipulation of the complex Hacd1-dependent lipid balance may represent an alternative, 
non-invasive therapeutic strategy in HACD1-related or other congenital myopathies. 
Although these changes might influence different steps of myoblast fusion such as myoblast 
migration or membrane merging, they are all expected to favor membrane fusion per se. First, 
LPC has been reported to inhibit several events of membrane fusion (Reporter and Raveed, 
1973; Chernomordik et al., 1993; Yeagle et al., 1994; Ciechonska and Duncan, 2014), 
presumably because its inverted cone-shape interferes with the negative membrane curvature 
required for the hemifusion step (Chernomordik and Kozlov, 2005). Accordingly, LPC can 
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reversibly inhibit myoblast fusion, although its effect may depend upon its concentration and 
the stage of fusion (Leikina et al., 2013; Teng et al., 2015). Our data showed that Hacd1 
regulates the LPC drop normally observed during myoblast differentiation. We suggest that 
this drop in total membranes increases myoblast permissiveness to fusion and that the failure 
of this drop observed in Hacd1-deficient cells constitutes a major determinant of myoblast 
fusion impairment in HACD1-deficient conditions. Whether this LPC drop is of significant 
importance for specific membrane compartments, including the plasma membrane, will 
require further analyses. In parallel, longer acyl chains of VLCFAs are proposed to fill the 
voids created during membrane bending and to stabilize strong membrane curvatures 
(Schneiter et al., 2004; Chernomordik and Kozlov, 2005). Like other fusion processes, 
myoblast fusion involves a hemifusion stage for plasma membranes, during which lipids from 
the two merging outer layers are mixed (Chernomordik and Kozlov, 2005; Leikina et al., 
2013), followed by the formation of a fusion pore inducing cell content mixing. These two 
sequential steps necessitate strong membrane curvature that would be favored by VLCFAs, in 
accordance with the defective vesicle fusion observed during cytokinesis in plants lacking 
VLCFA-containing sphingolipids (Molino et al., 2014). Finally, membrane fluidity is a well-
known determinant of successful membrane fusion (Maxfield and Tabas, 2005) and in 
myoblasts, it could also promote fusion by concentrating fusion-associated factors or lipid 
rafts at sites of contact between activated myoblasts (Abmayr and Pavlath, 2012). During 
myoblast differentiation, we showed that Hacd1 activation yields increased levels of MUFAs 
at the expense of SFAs, a mechanism that likely participates to the increased membrane 
fluidity and would explain the enhanced myoblast fusion reported following addition of 
unsaturated fatty acids, whereas saturated fatty acids or cholesterol, a membrane rigidifier, 
tend to inhibit fusion (Prives and Shinitzky, 1977; Nakanishi et al., 2001; Lee et al., 2009; 
Briolay et al., 2013).  
In conclusion, the results presented here provide a unifying genetic control accounting for 
several changes in lipid balance that likely confer permissiveness for myoblast fusion in an 
additive manner. This promoting function would result from the increase in Hacd1-fl 
expression following a muscle-enriched splicing mechanism. In addition to increasing the 
VLCFA content through its HACD enzymatic activity, HACD1-FL would modify MUFA 
and LPC levels indirectly, by regulating their respective biosynthetic pathways. Desaturation 
of SFAs into MUFAs mostly relies on the desaturase activity of ER-resident stearoyl-CoA 
desaturase proteins (Guillou et al., 2010), and in yeast, physical interactions described 
between the desaturase Ole1 and proteins of the VLCFA elongation complex (Miller et al., 
2005) suggest functional cross-talk between the two enzymatic pathways. The LPC level 
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results from a more complex mechanism since it can be generated either by the cleavage of 
phosphatidylcholine by phospholipase A2 or by the lecithin-cholesterol acyl-transferase 
activity. Interestingly, it has been shown that increased LPC synthesis constitutes an 
important step leading to atherosclerosis (Schmitz and Ruebsaamen, 2010). LPC is also 
released by several tumor cell lines and because of autotaxin activity, generates the potent cell 
motility activator lysophosphatidic acid (Gotoh et al., 2012). Thus, identification of splicing 
factors that upregulate Hacd1-fl and reduce LPC expression, which is an issue in 
developmental myology, might be of wider medical interest. 
Further studies will be required to precisely assess the role of Hacd1 on the metabolism, 
subcellular localization and function of these candidate lipids, as well as on the indirect 
modulation of pathways regulating LPC and unsaturated fatty acids contents. 
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Materials and Methods 
Mice and myoblasts 
The Hacd1 knockout recombination vector (PRPGS00067_A_B09) was obtained from the 
Knockout Mouse Project Repository (KOMP; https://www.komp.org) and was electroporated 
into C57BL/6N ES cells. All experiments were performed on mice generated from two 
independent ES clones. Matings between Hacd1+/- mice generated control (wild type and 
Hacd1+/-) and Hacd1 knockout (Hacd1-/-) mice for all the described experiments.  
The ANSES/EnvA/Upec Ethics Committee (C2EA – 16; www.enseignementsup-
recherche.gouv.fr) approved the experiments performed on mice (approval numbers 11/11/15-
2 and 20/12/12-16). 
sh-Hacd1 and control myoblasts were obtained by selecting puromycin-resistant clones of 
C2C12 myoblasts, respectively transfected with two different shRNA pGIPZ lentiviral 
vectors against Hacd1 exon 4 or a control vector (OpenBiosystems). 
Statistical analysis 
A t-test-ANOVA with repeated measure factor was applied to paired data, i.e. in the case of 
measurement of fibre number, size, nuclear content or PAX7-positive cell content on muscle 
sections, as well as mass measurements of paired muscles in mice. Student T test was used for 
all other analyses and Welch modification was applied when sample number was low (n < 4). 
Data are expressed as mean ± standard error of the mean and differences were considered 
significative when P < 0.05. 
Experimental details 
Experimental details of regeneration experiments in dogs and mice; immunological and 
histological staining; muscle section analyses; tetanic force measurement; PCR, RT-PCR and 
RT-qPCR experiments; fluidity; HACD activity measurements; phospholipid analyses; co-
affinity purification experiments; additional ethics statement are available in the 
Supplementary information file. 
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Figure legends 
Figure 1.  Myopathy in Hacd1-/- mice.  
(A) Weight gain in Hacd1-/-, Hacd1+/- and wild type (WT) mice from birth to postanatal week 
three (n = 11, 15 and 12, respectively). (B) Photograph of gastrocnemius muscles from WT 
(left) and Hacd1-/- (right) 6-mo-old mice. (C) Mean mass of gastrocnemius and tibialis 
anterior (TA) muscles from 6-mo-old Hacd1-/-, Hacd1+/- and WT mice (gastrocnemius: n = 5, 
3 and 4 mice, respectively; TA: n = 9, 7 and 8 mice, respectively). (D) Mean absolute 
maximal force of TA muscles from Hacd1-/-, Hacd1+/- and WT mice (n = 16, 12 and 16, 
respectively). Error bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; 
***: P < 0.001. 
Figure 2.  Defective myofibre growth in HACD1-deficient dogs and mice.  
(A and B) H&E-stained transverse sections of biceps femoris muscles from 5-mo-old control 
(A) and HACD1cnm/cnm CNM-affected (B) dogs showing hypotrophic fibres in (B). (C) 
Average myofibre diameter (in µm) in 3- to 4-y-old control and HACD1cnm/cnm dogs (n = 3 for 
each genotype; ≥ 460 fibres examined per dog). (D) Percent distribution by diameter (µm) of 
myofibres analyzed in (C). (E and F) H&E-stained transverse sections of TA muscles from 3-
mo-old control (i.e., WT or Hacd1+/- (E)) and Hacd1-/- (F) mice showing fibre size 
disproportion in (F) (n = 3 for each condition). (G) Mean fibre diameter in TA muscles from 
3-mo-old control and Hacd1-/- mice (n = 3 for each group; ≥ 780 fibres per mouse). (H) 
Percent distribution by diameter (µm) of myofibres analyzed in (G). (I) Mean number of total 
fibres in TA muscles from 3-mo-old control and Hacd1-/- mice (n = 5 for each group). 
Bars: 100 µm. Error bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; 
***: P < 0.001. 
Figure 3.  Defective myoblast fusion in HACD1-deficient dogs and mice.  
H&E-staining of muscle transverse sections before (A and B) and at Day 15 after notexin 
injection (D and E) in control (A and D) and HACD1cnm/cnm (B and E) dogs. Bars: 200 µm. (C 
and F) Percent distribution by diameter (µm) of myofibres from dog muscles before (C) and 
at Day 15 after notexin injection (F) (n = 1 for each genotype; ≥ 730 fibres examined per 
dog). (G and H) Immunofluorescence for Dystrophin (green) on TA sections at Day 15 after 
notexin injection in control (G) and Hacd1-/- (H) mice. Nuclei are in blue. Bars: 100 µm. (I) 
Mean fibre diameter in TA muscles at Day 15 after notexin injection in control and Hacd1-/- 
mice (n = 3 and 4, respectively; ≥ 1780 fibres per mouse). (J) Percent distribution by diameter 
(µm) of myofibres analyzed in (I). (K) Nuclear content of fibres (n = 3 for each group; ≥ 600 
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fibres per mouse). Error bars correspond to standard error of the mean. *: P < 0.05; 
**: P < 0.01; ***: P < 0.001. 
Figure 4.  Defective myoblast fusion in normally differentiating HACD1-deficient 
myoblasts.  
(A and B) Immunodetection on muscle primary cell cultures from control or Hacd1-/- 
newborns at Day 2 of differentiation of the Myosin Heavy Chains (MHC, green). Nuclei are 
in blue. Bars: 100 µm. (C) Unchanged differentiation index in HACD1-deficient myoblasts, 
i.e., percentage of nuclei contained in MHC-positive cells (n = 5 for each newborn group; ≥ 
1000 nuclei per sample). (D) Decreased fusion index in HACD1-deficient myoblasts, i.e., 
average number of nuclei per myotube (n = 5 for each newborn group; ≥ 100 myotubes per 
sample). (E) Percent distribution of myotubes analyzed in (D) by their number of nuclei. 
Error bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; 
***: P < 0.001.  
Figure 5.  Upregulation of the muscle-specific, Hacd1-full length (Hacd1-fl) isoform 
during muscle fibre development.  
(A and B) X-Gal staining of a Hacd1+/- embryo at E12.5 (A), TA muscles (B) from a Hacd1-/- 
mouse at Day 15 after injection of NaCl (left) or notexin (right). (C) Dissected fibres from the 
notexin-injected muscle shown in (B) showing X-Gal staining in a regenerative fibre 
(centralized nuclei, in blue). Bar: 20 µm. (D) RT-PCR experiments showing expression of 
Hacd1 transcripts in mouse tissues and embryos. (E to H) Expression of Hacd1 transcripts 
during differentiation of primary muscle cells (E and F) and C2C12 cells (G and H) revealed 
by RT-PCR experiments (E and G) or RT-qPCR experiments (F and H) showing fold-change 
from proliferation for each isoform (n = 3 for each condition). (I) RT-qPCR experiments for 
Hacd1-fl and Hacd1-d5 isoforms in TA muscles from wild type mice, either non injected 
(n = 4) or at Day 6 (n = 3) or Day 15 (n = 4) after notexin injection. Error bars correspond to 
standard error of the mean. *: P < 0.05; **: P < 0.01; ***: P < 0.001. 
Figure 6.  Activity of HACD1 isoforms and role of HACD1-fl in myoblast fusion.  
(A) Affinity-purified 3xFLAG-tagged HACD1 isoforms incubated with [14C]3-
hydroxypalmitoyl-CoA (3-OH FA) and separated by normal-phase thin layer 
chromatography. (B) Shutdown of PHS1 in a yeast strain carrying PHS1 under control of a 
tetracycline (doxycycline; DOX)-dependent promoter leads to a lethal phenotype, rescued 
only by the active wild type HACD1-fl isoform. Cells were serially diluted at 1:10. (C) At 
Day 5 of differentiation, sh-Hacd1 cells failed to form elongated myotubes, a phenotype 
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rescued only by re-expression of the wild type HACD1-fl (sh-Hacd1+fl) isoform. 
Bars: 200 µm. (D) Fusion index of sh-Hacd1 cells and sh-Hacd1 cells re-expressing HACD1 
isoforms (n = 3 for each condition).  
Figure 7.  HACD1 regulates lipid balance and membrane fluidity in myoblasts.  
(A) Lysophosphatidylcholine (LPC) content, expressed as the percentage of total 
phospholipids, in proliferation and at Day 3 of differentiation. (B) Ratio of C18-26 to C10-16 
phospholipid fatty acids in proliferation and at Day 3 of differentiation. (C) Proportions of 
saturated (SFA), monounsaturated (MUFA) or polyunsaturated (PUFA) fatty acids at Day 3 
of differentiation. (D) Fluorescence anisotropy (r, inverse of fluidity) measured at Day 3 of 
differentiation. (E) Proposed model for the role of Hacd1-fl during muscle fibre development. 
Error bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; 
***: P < 0.001.  
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Supplementary material 
Animals, Materials and Methods 
Generation of Hacd1 knockout mice 
The Hacd1 knockout recombination vector (PRPGS00067_A_B09) was obtained from the 
Knockout Mouse Project Repository (KOMP) (https://www.komp.org/). The targeting vector 
carried loxP sites upstream of exon 2 and downstream of exon 4 of Hacd1 gene and a NeoR cassette 
flanked by two loxP sites upstream of exon 2. In order to generate ES cells heterozygous for the 
targeting vector, the construct was linearized using AsiSI (New England BioLabs), then purified. 
The vector was electroporated into C57BL/6N ES cells and G418-resistant clones were screened for 
homologous recombination by PCR (Long Range PCR, dNTPack (Roche)) using the following 
primers (Forward primer: 5’ATG GGT GCC TAT TTT CAG TCA GTC A-3’; Reverse primer: 
5’AAC TGG TTC CTT CAC GAC ATT CAA C-3’). A second PCR was performed to control the 
presence of loxP site upstream of exon 5 (Forward primer: 5’-TCT TAG GAA GGA GAT GGC 
GCA-3’; Reverse primer: 5’-AGC CAG CAG GGC TAT AAA CTG AGA C-3’). Chromosomal 
integrity of the selected clones was checked by karyotyping and Southern blotting was performed to 
confirm the presence of a single insertion. 
Positive clones were then injected into BALB/c blastocysts and chimeric males were mated with 
C57BL/6N females. Presence of the Hacd1 targeting allele in individuals from the progeny was 
assessed by PCR (Forward primer: 5’-TTC ATG TGAA CAC ATT TCT ATT C-3’; Reverse 
primer: 5’-TGT CTT TTT CTC TAA GCT CCT C-3’) (PCR was performed as explained below for 
RT-PCR). Mice carrying the Hacd1 targeting allele were bred with PGK-Cre mice to generate 
Cre-positive mice carrying a recombinant, knockout Hacd1 allele (Hacd1+/- mice). PGK-Cre 
transgene was eliminated at the following generation and crosses between Hacd1+/- mice generated 
control (wild type and Hacd1+/-) and Hacd1 knockout (Hacd1-/-) mice for the described 
experiments. All experiments were performed on mice generated from two independent ES clones. 
Muscle dissection and regeneration experiment in mice 
Male mice were euthanized by cervical dislocation and the tibialis cranialis (TA) and 
gastrocnemius muscles were dissected and frozen as described below. For regeneration 
experiments, 15 µl of Notexin (Latoxan) (10-5M diluted in 0.9% NaCl) were injected into the left 
TA, and 15 µl of 0.9% NaCl into the right TA (Day 0) of 10 month-old males. Mice were 
euthanized on Day+6 or Day+15 following notexin injection and TA muscles were dissected and 
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either frozen for RT-qPCR or immunofluorescence experiments, or stained in X-Gal solution (see 
below).  
X-Gal staining of mouse embryos and muscles 
A C57BL6/N mouse female crossed with a Hacd1+/- male was euthanized by cervical dislocation at 
stage E12.5 of gestation. The uterus was dissected in PBS and embryos were extracted and fixed for 
1 h in 4% formaldehyde in PBS at 4 °C, then rinsed and stained overnight at 33 °C in a solution of 
PBS containing 1% Tween 20, 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM 
MgCl2, 0.4 mg/ml X-Gal dissolved in DMSO (all reagents were from Sigma). Embryos were then 
rinsed in PBS. No staining was observed in Hacd1+/+ embryos, other than that typically-occurring 
very lightly in the intestinal tract. The same protocol was applied to TA muscles at Day+6 
following notexin injection. 
Maximal muscle force measurement in mice 
Tibialis anterior muscles of 6-mo-old males were evaluated by the measurement of in situ isometric 
muscle contraction in response to nerve stimulation as previously described (Schirwis et al., 2013). 
Mice were anaesthetised using a pentobarbital solution (ip, 60 mg/kg). Feet were fixed with clamps 
to a platform and knees were immobilized using stainless steel pins. The distal tendons of muscles 
were attached to an isometric transducer (Harvard Bioscience) using a silk ligature. The sciatic 
nerves were proximally crushed and distally stimulated by bipolar silver electrode using 
supramaximal square wave pulses of 0.1 ms duration. All data provided by the isometric transducer 
were recorded and analyzed on a microcomputer, using PowerLab system (4SP, AD Instruments). 
All isometric measurements were made at an initial length L0 (length at which maximal tension was 
obtained during the tetanus). Responses to tetanic stimulation (pulse frequency from 6.25, 12.5, 25, 
50, 100 and 143 Hz) were successively recorded. Absolute maximal tetanic force was determined. 
Muscle mass (m) was measured to calculate specific maximal force (= absolute maximal force/m). 
All procedures were performed in accordance with national and European legislations and all 
experimental protocols have been approved by the French Departmental Direction of Animal 
Protection (agreement 75-1102). 
Muscle biopsy samples and regeneration experiment in dogs 
Biceps femoris biopsy samples were collected through an open surgical procedure either once in 5-
mo-old or 3- to 5-y-old healthy or HACD1cnm/cnm Labrador Retrievers or sequentially before (T0) 
and 4, 15, 30 and 90 days after the notexin injection in 36- to 48-month-old healthy or CNM 
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Labrador Retrievers. The venom injection was performed as previously described (Sharp et al., 
1993; Wilson et al., 1994). 
Ethics statement 
The ANSES/EnvA/Upec Ethics Committee (C2EA – 16; www.enseignementsup-recherche.gouv.fr) 
approved the experiments performed on mice (approval numbers 11/11/15-2 and 20/12/12-16). 
Labrador Retrievers were dogs maintained in our research colony, and samples used in this study 
were frozen samples obtained in the 1990s by one of the co-authors (SB). At the time they were 
sampled, there was no animal welfare committee at the Ecole nationale vétérinaire d'Alfort; 
however, SB is a certified veterinarian and was accredited by the Veterinary Division of the French 
Ministry of Agriculture to perform research on animals. 
Cell culture 
HEK 293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, St. Louis, 
MO), supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin, seeded in 
dishes coated with 0.3% collagen respectively. C2C12 myoblasts were grown in DMEM (PAA) 
containing 4.5 g/l glucose, supplemented with 15% FBS (PAA) and penicillin/streptomycin. Cells 
were maintained at 37 °C in a saturated humidity atmosphere containing 5% CO2. For the 
differentiation of C2C12 myoblasts, fetal bovine serum was replaced by 2% horse serum (Biowest) 
when myoblasts reached 70-80% confluence. For fatty acid supplementation, 10 mM fatty acids 
(Sigma) stock solution maintained at -20 °C in ethanol in glass tubes, were dissolved in DMEM 
supplemented with 0.25 mM fatty acid-free BSA (Sigma, A6003) at 37 °C for 5 min under strong 
agitation. Fatty acid solutions were filtrated through 0.2 µm filters (Dutscher, 146560) and diluted 
in differentiation medium (DMEM + 2% of horse serum) at a final concentration of 5 µM from the 
first day of differentiation (D0). The fusion index was calculated as the mean number of nuclei per 
myotube at day 5 of differentiation. Myotubes were defined as myosin heavy chain-positive cells 
containing at least 2 nuclei. 
Primary myoblasts were obtained by dissection of hindlimb muscles from 5-day-old wild type, 
Hacd1+/- and Hacd1-/- pups. Muscles were digested in PBS containing 0.5 mg/ml collagenase 
(GIBCO 17101) and 3.5 mg/ml dispase (GIBCO 17105) for 2 h at 37 °C. Cell suspension was 
filtered through a 40 µm cell strainer and pre-plated in DMEM + 15% FBS for 4 h at 37 °C, 5% 
CO2. Non-adherent myogenic cells were collected and plated in IMDM (GIBCO 31980) + 20% 
FBS onto Ibidi dishes (Biovalley 80426) coated with collagen (Sigma C7661). Differentiation was 
triggered by changing the culture media to IMDM + 2% of horse serum for 2 days. 
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Generation of sh-Hacd1 cells  
Two shRNA pGIPZ lentiviral vectors designed to target Hacd1 exon 4 (V2LHS_5923 
(GCTCATTACTCACAGTATA) and V2LHS_252516 (CTCATTACTCACAGTATAA)) and a 
control vector (RHS4349; OpenBiosystems) were transfected into C2C12 cells using Arrest-in 
(OpenBiosystems). After 48h, transfected cells were selected with puromycin (2 mg/ml; 
Invitrogen). Individual clones were picked after 10 days of selection and shRNA efficiency was 
checked by RT-qPCR. Initial experiments conducted in parallel in one V2LHS_5923 and one 
V2LHS_252516 clone proved phenotypic similarity. Clone V2LHS_252516 clone (named sh-
Hacd1 cells) was then selected for the series of functional experiments. Control cells correspond to 
cells transduced with the control vector. 
Transduction of HACD1 isoforms 
For expression of shRNA-resistant isoforms in control and sh-Hacd1 cells, cDNAs from the three 
canine HACD1 isoforms were isolated by RT-PCR on mRNA extracted from muscles of wild type 
(HACD1-fl and –d5 isoforms) and CNM-affected (HACD1-167 isoform) Labrador Retrievers. 
Three silent mutations (GCTCATCACACATAGTATA) were introduced into exon 4 of HACD1-fl 
and HACD1-d5 cDNAs by PCR and a MYC tag was introduced at the 5’ end of the 3 isoforms 
using the following primers. Forward primer for all isoforms: 
GATCCTCGAGACCATGGCATCAATGCAGAAGCTGATCTCAGAGGAGGACCTGGCTGCA
CTTATGGCGTCCAGCGAGGAG; Reverse primer for HACD1-fl and HACD1-167: 
AGATGCGGCCGCTTAATCATCCTTTTCTACAATCACTTCTC; Reverse primer for HACD1-
d5: AGATGCGGCCGCTCACCAACAACCCCGACAGGA. PCR products were cloned into the 
pCR4-TOPO vector (Life Technologies). After sequencing, cDNAs were cloned in the MSCV-
IRES-BlasticidinR (MSCV-IRES-bsr) retroviral vector using EcoRI restriction. The HACD1-fl-
Y171A mutation (ATCATCTTAGCTCCTGTCGGGGT) was obtained by PCR from the HACD1-fl 
shRNA-resistant construct and cloned as described. 
Retroviral particles were produced by transient triple transfection of HEK293T cells with 
XtremeGene 9 reagent from Roche, according to manufacturer's instructions, using a 2:1:1 ratio of 
MSCV-ires-bsr, LTR-env and CMV-gag-pol (a kind gift of Olivier Albagli). Retroviral 
supernatants were collected 48 h after transfection and concentrated on Amicon Ultra-15 centrifugal 
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filter units (100 kDa cut-off, Millipore). C2C12 cells were spinfected by a 1 h centrifugation (300 
g) in the presence of retroviral supernatant and 8 µg/ml polybrene (Sigma). 
Tranduced cells were selected with blasticidin (5 µg/ml; Invitrogen). Plasmid expression was 
checked by RT-qPCR and immunostaining. 
Extraction of total RNA, RT-PCR and RT-qPCR analysis 
Mouse muscle samples were snap frozen in liquid nitrogen and stored at -80 °C. Total RNAs were 
isolated from C2C12 myoblasts and mouse samples with RNA Nucleospin Kit (Macherey-Nagel) 
according to the manufacturer’s protocol. Purity of RNAs was assessed by a ratio of absorbance at 
260 nm and 230 nm > 1.7. RNA quality was checked on agarose gel. One microgram of RNA was 
used for reverse transcription with the Maxima First Strand cDNA Synthesis Kit for RT-qPCR 
(Fermentas). cDNA were amplified using the Maxima SYBR Green qPCR Master Mix (2X) 
(Fermentas). PCR reactions were performed with Taq DNA Polymerase from MP Biomedicals on a 
Mastercycle Eppendorf thermocycler. qPCR reactions were performed on a Roche Light Cycler 
Carousel-based system 2.0 (Roche). 
Expression of mouse Hacd1 and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) mRNAs 
were examined by PCR using first-strand cDNAs from various mouse tissues and embryonic stages 
(Mouse MTC panel I; Clontech, TAKARA Bio, Palo Alto, CA, USA) with primer pairs (for Hacd1, 
Hacd1-For-2/Hacd1-Rev-2; and Gapdh, Gapdh-For/Gapdh-Rev). These and the other primers used 
for quantification of gene expression are listed in Table S1. All PCR and qPCR products were 
examined qualitatively on agarose gels. All presented RT-qPCR results were normalized to Tbp1 
(Hacd1 expression during muscle regeneration), Hprt1 (Pax7 expression) or CycloB (all other 
cases) gene expression. 
Immunofluorescence and histological staining  
Control, sh-Hacd1 or sh-Hacd1 cells expressing shRNA-insensitive isoforms were grown for 48 h 
on a glass coverslip (Menzel-Glaser) and then briefly rinsed three times with PBS (PAA), fixed for 
15 min with 4% formaldehyde and rinsed with PBS. Cells were permeabilized for 10 min with 
PBS-0.1% Triton (Sigma), rinsed 3 times with PBS, and blocked with PBS-1% BSA (Sigma) for 
1 h before incubation with antibodies. Primary anti-Calnexin (rabbit polyclonal, Sigma, 1:200), 
anti-Myc (mouse 4A6, Millipore, 1:200), and anti-myosin heavy chain (mouse MF20, DSHB, 
1:500) antibodies were incubated overnight at 4 °C and revealed using secondary Alexa 488 goat 
anti-rabbit (1:500) and Alexa 555 goat anti-mouse (1:500) (Invitrogen). Nuclei were stained with 
DAPI (4’,6’ diamidino-2-phenylindol ) 1:4000 for 10 min at RT and slides were mounted using 
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Fluorescent mounting medium (Dako). Alternatively, they were mounted in aqueous mountant 
containing the chromatin stain DAPI (1.5 µg/ml) (Vectorshield). 
Muscle biopsy samples from dogs and muscles from mice were snap-frozen in isopentane cooled in 
liquid nitrogen and stored at −80 °C. Transverse-sections (10 µm thickness) were stained with 
hematoxylin-eosin (H&E) or in an ATPase staining solution following a preincubation at pH = 9.4 
or immunostained as previously described for cells with anti-Pax7 (mouse monoclonal, DSHB, 
1:20), anti-V5 epitope (rabbit polyclonal, Abcam, 1:500, anti-Ryr1 (mouse Abcam 3C, 1:100) 
primary antibodies. For Dystrophin immunostaining, fixation was performed with acetone/methanol 
v/v at -20 °C for 15 min and immunostaining was pursued with anti-Dystrophin (mouse 
monoclonal, Novocastra, 1:20) antibody. For both anti-PAX7 and anti-Dystrophin antibodies, 
Mouse Ig Blocking Reagent (MOM kit, Vector, MFB-2213) was used following the manufacturer’s 
instructions. Alexa 488 or 594 goat anti-rabbit (1:500) and Alexa 488 or 555 goat anti-mouse 
(1:500) (Invitrogen) secondary antibodies were then used. Images were captured using an Axio 
Observer Z1 microscope (Zeiss) and analyzed using Photoshop CS3. 
Routine muscle histopathological evaluation was conducted on the basis of the H&E staining. 
Diameter and distribution of myofiber type were examined on ATPase 9.4 sections. Quantification 
of fiber number, size or nuclear content was performed on 7 randomly-selected fields (dog samples) 
or 3 sections separated by at least 30 µm (mouse samples). Morphometric quantification of the 
minimal Feret’s diameter was done using the Visilog software (Noesis) and quantification of fiber 
number and nuclear content was done using ImageJ (1.47v). In dog and mouse samples, 500 to 
1000 fibers and 700 to 1500 fibers, respectively, were analyzed for each section. 
Plasmid electroporation into murine skeletal muscle 
V5-tagged murine Hacd1-fl was generated by direct TOPO TA cloning of RT-PCR products into 
pcDNA3.1/V5-His TOPO (Invitrogen) (primer sequences Forward: 5'-
GTCACCATGGCGTCCAGTGAGGAG-3' Reverse: 5'-GTGTGTGGGAACCACTAAAT-3'). 
Expression vector was electroporated into tibialis cranialis (TA) muscles of 7-wk-old female 
C57BL/6 mice (2 mice bilaterally) according to (McMahon et al., 2001). Mice were anaesthetised 
with fentanyl/fluanisone (Hypnorm) and midazolam (Hynovel) and injected intramuscularly with 
bovine testes hyaluronidase (25 µl/muscle of 0.4 µg/µl solution in sterile saline) using an insulin 
syringe and 28 gauge needle. After 2 h, anaesthesia was deepened with isofluorane inhalation, and 
25 µl plasmid solution (0.5 µg/µl) was injected into the TA prior to transcutaneous electroporation 
performed by applying a potential difference of 81V across the muscle in 10 x 20 ms pulses at 1 Hz 
frequency (ElectroSquare Porator ECM 830, BTX). After 6 days, mice were euthanized by cervical 
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dislocation and the TA muscles were dissected and treated as described in the previous section. 
Yeast strain and media 
S. cerevisiae strain TH_3237 (MATa his3D1 leu2D0 met15D0 ura3D0 URA3::CMV-tTA 
pPHS1::KanMX4-TetO7-CYCTATA) (Mnaimneh et al., 2004) was obtained from Open Biosystems 
(Huntsville, AL). Cells were grown in synthetic complete (SC) medium (0.67% yeast nitrogen base, 
2% D-glucose, and nutritional supplements) but lacking histidine (SC-His) at 30 ˚C. 
Western blot analysis 
sh-Hacd1 cells expressing shRNA-insensitive isoforms were washed in PBS and put in lysis buffer 
(50 mM HEPES pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT, Complete 
protease inhibitor cocktail (Roche), 1 mM EDTA) for 30 min on ice. Lysates were sonicated and 
spun for 10 min at 10,000 g. After determination of protein contents using the Bradford method, 20 
µg of clarified lysates were separated by SDS-PAGE. Transfer was done on a PVDF membrane 
(Millipore). Membranes were blocked with TBS-5% skimmed milk for 1 h at RT and incubated 
with anti-MYC antibody (Mouse 9E10, Sigma, 1:2000) or mouse anti-α-Tubulin (mouse DM1A, 
Sigma, 1:5000) in TBS-0.1% Tween overnight at 4 °C. After washing, anti-mouse-HRP antibody 
(Amersham) was applied for 1 h at RT. After washing, antibody-bound proteins were visualised 
using the ECL+ kit (Amersham). Acquisition was done using a Fusion Fx5 (Vilber Lourmat). 
Quantification was performed using Photoshop CS3.  
Western blot analysis for yeast proteins was performed as described previously (Kihara and 
Igarashi, 2002), using the anti-FLAG antibody M2 (1 mg/ml; Stratagene, Agilent Technologies, La 
Jolla, CA, USA) and anti-Pgk1 antibodies (0.25 mg/ml; Molecular Probes, Life Technologies, 
Eugene, OR) as the primary antibodies, and HRP-conjugated anti-mouse IgG F(ab’)2 fragments (at 
1:7500 dilution; GE Healthcare Life Sciences, Buckinghamshire, UK) as the secondary antibodies. 
Labeling was detected using Pierce Western Blotting Substrate (Thermo Fisher Scientific, 
Waltham, MA, USA). 
Co-Affinity Purification (Co-AP) experiments in HEK293T 
cDNAs for cHACD1-fl, -d5 and -167 isoforms were cloned as baits in the pDEST27-GST Gateway 
vector (Invitrogen). cDNAs for cHACD1-fl, -d5 and -167 isoforms, and human HACD2, HACD3, 
HACD4, ELOVL1 to 7, KAR and TER genes were cloned as preys in the pCE-puro 3XFlag-1 vector. 
Human EIF2B1 cDNA was cloned in the pDEST-Myc Gateway vector (gift from Marc Vidal’s lab) 
as a control prey. For each interaction assay, GST-bait and Flag/Myc-prey expression vectors were 
co-transfected in HEK293T cells using calcium phosphate. Each Flag/Myc-prey vector was also co-
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transfected with GST vector alone. After 24 h, cells were harvested and lysed with lysis buffer (50 
mM HEPES pH = 7.4, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT, 1 mM 
EDTA, Complete protease inhibitor cocktail (Roche)) for 20 min on ice. Cell lysates were sonicated 
and pre-cleared by centrifugation for 10 min at 15,000 g at 4 °C. Pre-cleared lysates were incubated 
with Immobilized Glutathione beads (Perbio) for 1 h at 4 °C. Beads were then washed extensively 
three times with lysis buffer and then eluted with ½ lysis buffer and ½ loading buffer 2X (125 mM 
Tris pH = 7.4, 4% SDS, 20% glycerol, bromophenol blue) at 37 °C for 5 min. After denaturation, 
15 µg of pre-cleared lysates and a constant volume of eluates were separated by SDS-PAGE and 
transferred to a PVDF membrane (Millipore). FLAG-, MYC- and GST-tagged proteins were 
detected as described above, using mouse anti-FLAG (M2, 1:2000), mouse anti-MYC (9E10, 
1:2000) and rabbit anti-GST (1:2000) antibodies (Sigma), respectively. FLAG-/MYC-tagged 
proteins were first revealed, membranes were then stripped using Restore Western Blot Stripping 
Solution (Pierce) and GST-tagged proteins were revealed with ECL+ reagent (Amersham). 
Acquisition was done using Fusion Fx5 (Vilber Lourmat). 
HACD activity assay 
The assay was performed using 3-hydroxy[1-14C]palmitoyl-CoA (55 mCi/mmol; American 
Radiolabeled Chemicals, St. Louis, MO, USA) as described previously (Kihara et al., 2008). 
Lipids analyses 
Cell preparation 
C2C12 cells were rinsed using 0.9% NaCl, trypsinated and resuspended with proliferation medium. 
Cells were centrifuged at 4,000 g for 10 min and pellets were rinsed twice using 0.9% NaCl. Tubes 
containing dry pellets were filled with non-reactive argon to prevent aerial oxidation of samples and 
then immediately frozen at -80 °C. 
 
Reagents 
LCMSMS quality grade solvents were purchased from Fischer Scientific (Illkirch, France). 
Heptadecanoïc acid, tricosanoic acid, pentafluorobenzyl bromide, N,N'-diisopropylethylamine, 
potassium hydroxide and BHT were purchased from Sigma Aldrich (Saint-Quentin Fallavier, 
France). Di-myristoyl phosphatidylcholine (DMPC), 19:0-lysophosphatidylcholine (19:0-LPC), di-
myristoyl phosphatidylethanolamine (DPME), di-myristoyl phosphatidylserine (DMPS), d18:1-17:0 
sphingomyelin (17:0-SM) were from Avanti Polar Lipids (Coger, Paris, France). 
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Quantitation of total fatty acids by GC-MS 
Tissues (ca. 10 mg) were saponified with 1 ml of ethanolic potassium hydroxide (final 
concentration 0.6 N) containing heptadecanoic acid (10 µg), tricosanoic acid (250 ng) used as 
internal standards (IS) and 50 mg/l of BHT. Samples were incubated at 56 °C for 45 min under 
argon. Saponified fatty acids were extracted with 1 ml of HCl 1.2 M and 2 ml of hexane. After 
evaporation of the organic upper phase under vacuum fatty acids were derivatized to 
pentafluorobenzyl esters with 5 µl of pentafluorobenzyl bromide, 5 µl of diisopropylbenzylamine 
and 100 µl of acetonitrile at room temperature for 30 min. Derivatized fatty acids were further 
extracted with 1 ml of water and 2 ml of hexane. The organic phase was evaporated under vacuum. 
Finally fatty acids were dissolved in 100 µl prior to GC-MS quantification. 
Fatty acids esters (1 µl) were injected in split mode on a HP7890A Gas Chromatograph equipped 
with an HP7683 injector and a HP5975C Mass Selective Detector (Agilent Technologies). 
Chromatography was performed using a HP-5MS fused silica capillary column (30 mm x 0.25 mm 
inner diameter, 0.25 m  film thickness, Agilent Technologies). The GC-MS conditions were as 
follows: carrier gas, helium at a flow-rate of 1.1 ml/min; injector temperature, 250 °C, split mode; 
oven temperature 140 °C, increased at 5 °C/min to 300 °C, and held for 10 min. The mass 
spectrometer was operated under negative chemical ionization mode with methane as reactant gaz. 
The ion source temperature and the quadrupole temperature were 150 °C and 106 °C, respectively.  
Quantitation of fatty acids was performed by calculating their relative response ratios to 
heptadecanoic acid and tricosanoic acid (IS). For this purpose molecular ion responses obtained in 
negative SIM mode were used. 
 
Quantitation of PC, SM, PS, PE, PI by LCMS-MS 
Cells were spicked with DMPC (1.323 nmol), 19:0-LPC (1.380 nmol), DMPE (1.398 nmol), DMPS 
(1.083 nmol), 17:0-SM (1.194 nmol) used as internal standards and total lipids were further 
extracted according to the method of Folch et al. (Folch et al., 1957). 
Analysis of phospholipids was conducted by LCMS-MS in MRM mode as previously described 
(Vial et al., 2014). 
Membrane fluidity assay  
Plasma membrane fluidity was estimated by fluorescence anisotropy (r) as described (Bastiaanse et 
al., 1995; Le Borgne et al., 2012). (r) measurements were conducted using 1,6 diphenyl 1,3,5 
hexatriene (DPH) as a probe. In polarized excitation light, a high r value reflects increased 
rotational lifetime of DPH that happens when DPH orientation is stabilized in less fluid membranes. 
Cultured cells were rinsed, harvested and centrifuged at 1,000 g for 5 min at 4 °C. The resulting 
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pellets were resuspended in Opti-MEM® Reduced Serum Medium (Life Technologies, Saint 
Aubin, France) at a concentration of one million cells per ml. Two milliliters of cell suspension 
were placed into a 1 cm path length spectroscopic quartz cuvette (VWR International, Limonest, 
France). The cells were stirred and maintained in a thermostatically controlled chamber. After 6 
min at 37 °C, 2 µl of the fluorescent probe DPH (1 mM in tetrahydrofuran) were added to label 
plasma membranes. r was measured at 37 °C 10 min after addition of the probe; after this first 
series of measurement, the temperature of the chamber was gradually reduced and anisotropy was 
measured at 35, 30, 25, 20, 15, 10 and 5 °C. Data were expressed as mean ± s.e.m. of three to five 
independent experiments. 
Statistical analysis 
ANOVA with repeated measure factor was applied to paired data, i.e. in the case of measurement of 
fiber number, size, nuclear content or PAX7-positive cell content on muscle sections, as well as 
mass measurements of paired muscles in mice. Student T test was used for all other analyses and 
Welch modification was applied when sample number was low (n < 4). Data are expressed as mean 
± standard error of the mean and differences were considered statistically significant when P < 0.05. 
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Legends to Supplementary Figures 
 
Supplementary Fig. 1. Generation and analysis of Hacd1 knockout mice. (A) Representation of 
the Hacd1 locus, the structure of the targeting vector, and the organization of the rearranged Hacd1 
knockout allele after CRE-mediated recombination. (B) PCR genotyping of wild type, Hacd1+/- and 
Hacd1-/- mice. (C) RT-qPCR experiments for expression of Hacd1 isoforms and Hacd2 and Hacd3 
genes in TA muscles from wild type and Hacd1-/- mice (n = 3 for each condition). Note that 
expression of Hacd2 and Hacd3 genes was not modified in Hacd1-KO mice. Hacd4 expression was 
not observed in either condition (data not shown). (D) Tibial length in wild type or Hacd1+/- 
(control) and Hacd1-/- 6 mo-old mice (n = 9 and 4 mice, respectively). (E) Mean specific maximal 
force (i.e., the ratio of absolute force to muscle mass) of TA muscles from Hacd1-/-, Hacd1+/- and 
wild type mice (n = 8, 6 and 8, respectively). (F) Photographs of a control and a Hacd1-/- 12-mo-old 
mouse. Note the kyphosis (red arrow) in the Hacd1-/- mouse. (G) H&E-stained transverse-sections 
of TA muscles at Day 6 after notexin injection in control and Hacd1-/- mice. Bars: 100 µm. Error 
bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; ***: P < 0.001. 
 
Supplementary Fig. 2. Weight gain and regeneration experiment in HACD1cnm/cnm dogs. (A) Total 
weight of HACD1+/cnm (control) and HACD1cnm/cnm pups of a same litter from birth to 28 days (n = 3 
for each group). (B) Total weight of HACD1+/cnm (control) and HACD1cnm/cnm 2-mo-old pups (n = 7 
and 13, respectively). Error bars correspond to standard error of the mean. *: P < 0.05. (C) H&E-
staining on muscle sections before (Day 0) and at Day 4, 15, 30 or 90 after notexin injection in 
HACD1+/cnm (control) and HACD1cnm/cnm muscles (n=1 for each condition). Bars: 200 µm. 
 
Supplementary Fig. 3. Progenitors in mice and expression of Hacd genes in myoblasts. (A and B) 
Immunofluorescence for PAX7 (in red) and Dystrophin (in green) on TA muscle cross-sections in 
control (A) and Hacd1-/- (B) mice. Nuclei are stained in blue. Asterisks point to PAX7-positive 
nuclei. (C) TA muscle area per PAX7-positive, satellite cells as observed in (A and B) (n = 3 mice 
per condition; more than 70 PAX7-positive cells examined per mouse). (D) RT-qPCR experiments 
for Pax7 expression in TA muscles from control and Hacd1-/- mice (n = 4 for each condition). Error 
bars correspond to standard error of the mean. (E) Expression of Hacd1 isoforms and Hacd2 and 
Hacd3 genes during C2C12 differentiation. Results of RT-qPCR experiments are expressed as a 
percentage of the level of the Hacd1-fl isoform at Day 2 (n = 3 for each condition). Error bars 
correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; ***: P < 0.001. 
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Supplementary Fig. 4. Conformation, expression, HACD activity and interactions of HACD1 
isoforms. (A) Topological structure of HACD1 isoforms predicted by the SOSUI program. Blue 
and pink residues are important and essential residues for HACD activity, respectively. Y171 
residue (red square) was replaced by an A residue in HACD1-FL-Y171A construct. (B) Expression 
of Myc-tagged HACD1 isoforms in the ER of C2C12 myoblasts decorated with an anti-Calnexin 
antibody. Nuclei are stained in blue. (C) In mouse muscle section, a V5-tagged HACD1-FL isoform 
also localizes at the sarcoplasmic reticulum decorated with an anti-RyR1 antibody. Bars: 10 µm. 
(D) Co-Affinity Precipitation (Co-AP) experiments between HACD1 isoforms and other members 
of the Very Long Chain Fatty Acid elongation complex. GST-tagged HACD1 isoforms or the 
empty GST vector (baits) were co-expressed in HEK293T cells with 3xFLAG-tagged protein 
members of the complex, or with the MYC-tagged EIF2B1 taken as a negative control (preys). 
Eluates were revealed for GST (upper panel) and FLAG/MYC (mid panel). Expression of 
FLAG/MYC-tagged proteins was checked in total lysates (lower panel). Data are representative of 
two to three independent experiments. (E) Quantity of the 2,3-trans hexadecenoic acid produced by 
each HACD1 isoform (Fig. 6A) and expressed as a percentage of the initial quantity of substrate. 
Error bars correspond to standard error of the mean. (F) Quantities of 3xFLAG-tagged HACD1 
isoforms in total yeast lysates (Fig. 6B) checked by western blotting (upper panel) and normalized 
to Pgk1 (lower panel).  
 
Supplementary Fig. 5. Characterization of sh-Hacd1 cells. (A) Expression of each Hacd1 isoform 
by RT-qPCR in sh-Hacd1 cells compared to control cells, both in proliferation and at Day 3 of 
differentiation. Data are expressed as a percentage of expression in control cells (n = 3 for each 
condition). Error bars correspond to standard error of the mean. *: P < 0.05; **: P < 0.01; ***: 
P < 0.001. (B-C) RT-qPCR experiments for Myogenin (B) and Myosin, heavy polypeptide 2, 
skeletal muscle, adult (Myh2) (C) gene expression in control and sh-Hacd1 cells during 
differentiation. Significant differences in expression between proliferation and during 
differentiation are shown for each condition. (D) Immunofluorescence in sh-Hacd1 cells at Day 5 of 
differentiation. Myosin heavy chains (MHC) are stained in green, actin in red and nuclei in blue. 
(E) Expression of Myc-tagged HACD1 isoforms in the ER of sh-Hacd1 myoblasts decorated with 
an anti-Calnexin antibody. Nuclei are stained in blue; bars: 10 µm. (F) Total cell lysates from sh-
Hacd1 and isoform-expressing sh-Hacd1 cells were subjected to immunoblotting using antibodies 
raised against Myc (upper panel) and Tubulin as a control of loading (lower panel).  
 
Supplementary Fig. 6. Unsaturation level of phospholipid fatty acid and membrane fluidity in 
sh Hacd1 cells. (A) Proportions of saturated (SFA), monounsaturated (MUFA) or polyunsaturated 
! 14!
(PUFA) fatty acids in proliferation (n = 3 for each condition; error bars correspond to standard error 
of the mean). (B) Fluorescence anisotropy (r, inverse of fluidity) measured at Day 3 of 
differentiation from 5°C to 37°C. For each cell type, the measured anisotropy increased when the 
temperature decreased, demonstrating that the DPH probe was in a lipid environment (n = 3 for 
each condition). Error bars correspond to standard error of the mean. *: P < 0.05; ***: P < 0.001. 
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Supplementary Table 1 
!
!
Primer!name!*! Sequence!
cHacd1:ex1F! 5’:CCTTCTACATCGCCATGACC:3’!
cHacd1:ex7R! 5’:CACCTTGTTCAGGGGGATCATT:3’!
cHacd1:fl:For! 5’:TATGGTGTGGCTCATCACACAT:3’!
cHacd1:fl:Rev! 5’:TGGCCCATTTAATGAAGTATGGC:3’!
cHacd1:d5:For! 5’:TATGGTGTGGCTCATCACACAT:3’!
cHacd1:d5:Rev! 5’:CAATGGTATATATGAGGCCATGG:3’!
cHacd1:167:For!! 5’:TCGCCATGACCTCGGGATAC:3’!
cHacd1:167:Rev! 5’:CAATGGTATATATGAGGCCATGG:3’!
Hacd1:ex1F! 5':GCCTGGCTCACCTTCTACAAT:3'!
Hacd1:ex7R! 5':CGTGGAGCACCTTTCTTCTC:3'!
Hacd1:For! 5’:ATATCCCGTTGGAGTTGCTG:3’!
Hacd1:Rev! 5’:CGTGGAGCACCTTTCTTCTC:3’!
Hacd1:fl:For! 5’:ATGAAGAGAGCGTGGTGCTT:3’!
Hacd1:fl:Rev! 5’:AAGGCGGCGTATATTGTGAG:3’!
Hacd1:For:2! 5’:ATGGCGTCCAGTGAGGAGGACGGC:3’!
Hacd1:Rev:2! 5’:TTAATCGTCCTTCTCCGCGATC:3’!
Hacd1:d5:For! 5’:TCACAGTATAAAACCCATACAATT:3’!
Hacd1:d5:Rev! 5’:GAGGCCATGGTTATGAGAAG:3’!
Hacd1:167:For! 5’:AATATCGCCATGACGGCCGGATAC:3’!
Hacd1:167:Rev! 5’:CAACGGTATATAGGAGGCCATG:3’!
cycloB:For!(Ppib!gene)! 5’:GATGGCACAGGAGGAAAGAG:3’!
cycloB:Rev!(Ppib!gene)! 5’:AACTTTGCCGAAAACCACAT:3’!
Hacd2:For! 5’:TGCTATAGGGATTGTGCCATC:3’!
Hacd2:rev! 5’:ACGGATAATTTCCGTGATTGTCC:3’!
Hacd3:For! 5’:GACGTGCAGAACCCTGCTATC:3’!
Hacd3:Rev! 5’:CTTCTGGACTGTGATGTTCACC:3’!
Hacd4:For! 5’:CAGCTCACAGAGAGAGTGATC:3’!
Hacd4:Rev! 5’:GAGTGTTTGACTGAGCCATGTC:3’!
Myogenin:For! 5’:CTACAGGCCTTGCTCAGCTC:3’!
Myogenin:Rev! 5’:AGATTGTGGGCGTCTGTAG:3’!
Myh2:For! 5’:ACTGGAGGGTGAGGTAGAGAG:3’!
Myh2:Rev! 5’:GCCTCCTCAGCTTGTCTCTTG:3’!
Gapdh:For! 5’:TGAAGGTCGGTGTCAACGGATTTGGC:3’!
Gapdh:Rev! 5’:CATGTAGGCCATGAGGTCCACCAC:3’!
Pax7:For! 5’:AGGCCTTCGAGAGGACCCAC:3’!
Pax7:Rev! 5’:CTGAACCAGACCTGGACGCG:3’!
TBP:For! 5’:ATCCCAAGCGATTTGCTG:3’!
TBP:Rev! 5’:CCTGTGCACACCATTTTTCC:3’!
Hprt1:For! 5':GTTAAGCAGTACAGCCCCAAA:3'!
Hprt1:Rev! 5':AGGGCATATCCAACAACAAACTT:3'!
!
*c:!canine!sequence;!otherwise:!mouse!sequence!
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Supplementary Table 2 
!
!
!
Legend. Repartition of (A) phospholipid species and (B) LPC species in control, sh-Hacd1 and 
isoform expressing sh-Hacd1 cells in proliferation and at Day 3 of differentiation. The amount of 
each species is expressed as its mole fraction to the total content (mol %; n = 3 for each condition). 
Superscript letters indicate significant differences (P < 0.05) with values reported in columns 
named using a one-letter-code. For example, the value of LPC in differentiating control cells 
(2.246±0.132a,b,c,d,f,g) is significantly different from all the other values [(a,b,c,d,f,g) columns], and 
LPC in differentiating sh-Hacd1 is significantly different from values of LPC in control and sh-
Hacd1+fl cells [(e,g) columns].!
!
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Supplementary Table 3 
!
!
!
Legend. Phospholipid fatty acid sorted by their content (A), length ratio (B) and saturation classes 
(C) of control, sh-Hacd1 and isoform expressing sh-Hacd1 cells in proliferation and at Day 3 of 
differentiation. Total phospholipid fatty acid methyl esters are presented depending of their 
aliphatic chain and saturation degree. The amount of each fatty acid is expressed as its mole fraction 
to the total free fatty acid content (mol %; n = 3 for each condition). Superscript letters indicate 
significant differences (P < 0.05) with values reported in columns named using the one-letter-code 
described in Supplementary Table 2.!






